Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371284 | 0.77 | ALDH1A1 (0.45) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL76493 | 0.76 | CYP19A1 (0.47) | KMT2AMEN1MAPTALDH1A1POLB | |
| SCHEMBL2370523 | 0.75 | MEN1 (0.44) | KMT2AMEN1MAPTALDH1A1POLB | |
| SCHEMBL22466023 | 0.75 | MEN1 (0.54) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| SCHEMBL22466020 | 0.75 | MEN1 (0.54) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| Hydrochloric Acid SCHEMBL29378443 | 0.74 | MEN1 (0.53) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| SCHEMBL5367360 | 0.74 | HTT (0.47) | KMT2AMAPTALDH1A1LMNAMAPK1 | |
| SCHEMBL85569 | 0.74 | AR (0.40) | KMT2AALDH1A1POLBMAPK1 | |
| SCHEMBL2717566 | 0.72 | MEN1 (0.48) | KMT2AMEN1MAPTALDH1A1SIRT6 | |
| SCHEMBL22466161 | 0.71 | MAPT (0.51) | KMT2AMEN1MAPTALDH1A1SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087582-A1 | Phenyl derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2004-05-06 | — | — | US | claimed |
| EP-1351938-A1 | PHENYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002057236-A1 | PHENYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-07-25 | — | — | WO | claimed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-7906516-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2011-03-15 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| US-20100256131-A1 | CARBONYL COMPOUNDS | TSAKLAKIDIS CHRISTOS | 2010-10-07 | — | — | US | disclosed |
| US-7579346-B2 | (R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]4-methylvaleramide, for example; inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors | MERCK PATENT GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-7579346-B2 | (R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]4-methylvaleramide, for example; inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors | MERCK PATENT GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | MERCK PATENT GMBH (DE) | 2008-01-03 | — | — | US | disclosed |
| US-20070265259-A1 | Proline Derivatives | MERCK PATENT GMBH (DE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265259-A1 | Proline Derivatives | MERCK PATENT GMBH (DE) | 2007-11-15 | — | — | US | disclosed |
| US-7273867-B2 | Phenyl derivatives | MERCK PATENT GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| US-7273867-B2 | Phenyl derivatives | MERCK PATENT GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| US-7273867-B2 | Phenyl derivatives | MERCK PATENT GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| US-20040087582-A1 | Phenyl derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2004-05-06 | — | — | US | disclosed |
| EP-1351938-A1 | PHENYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002057236-A1 | PHENYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265259-A1 | Proline Derivatives | F2, XPNPEP1, PRAP1 | KMT2A 3173/4885MEN1 867/4885MAPT 4809/4885 |
| US-20100256131-A1 | CARBONYL COMPOUNDS | F2, F11, PDHX | KMT2A 1530/4885MEN1 684/4885MAPT 3896/4885 |
| US-20080003214-A1 | Medicaments Comprising Carbonyl Compounds, And The Use Thereof | F2, PDHX, SDHB | KMT2A 3212/4885MEN1 1153/4885MAPT 2660/4885 |
| US-20040087582-A1 | Phenyl derivatives | F2, F11, SERPINC1 | KMT2A 2252/4885MEN1 2997/4885MAPT 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.